MTR-601 / Motorpharma, Motric Bio - LARVOL DELTA

Comprehensive SAR analysis of actomyolytics, drug candidates targeting the actomyosin complex. (PubMed, Eur J Med Chem) - "One molecule from this family, MPH-220, which was previously reported by Gyimesi et al. (2020), is currently undergoing phase 2 clinical trials in humans. In summary, our findings lay the groundwork for future drug development efforts aimed at targeting the final effectors of diverse physiological motor functions."

Journal

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals (clinicaltrials.gov) - P1 | N=89 | Completed | Sponsor: Motric Bio | Recruiting ➔ Completed | Trial completion date: May 2024 ➔ Oct 2024 | Trial primary completion date: Mar 2024 ➔ Oct 2024

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Cerebral Palsy • CNS Disorders • Dystonia • Genetic Disorders • Movement Disorders • Multiple Sclerosis • Muscle Spasticity • Musculoskeletal Diseases • Orthopedics

MTR-601-201: Study of the Oral Treatment MTR-601 in Cervical Dystonia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Motric Bio | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Dystonia • Movement Disorders

MTR-601-201: Study of the Oral Treatment MTR-601 in Cervical Dystonia (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Motric Bio

New P2 trial • CNS Disorders • Dystonia • Movement Disorders

[VIRTUAL] First-In-Class Anti-Spastic Drug Candidate (MPH-220) Efficiently Relaxes Spastic Muscles and Improves Motor Functions in Gait Disorder in Preclinical Studies (ISC 2021) - "Phase I clinical trials are scheduled for the beginning of 2021. Funded by the Hungarian National Research, Development and Innovation Office (NVKP 16-1-2016-0051 and PIACI-KFI-2019-00488)."

Preclinical • Cardiovascular • CNS Disorders • Movement Disorders • Muscle Spasticity • Vascular Neurology